Hubbry Logo
Good manufacturing practiceGood manufacturing practiceMain
Open search
Good manufacturing practice
Community hub
Good manufacturing practice
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Good manufacturing practice
Good manufacturing practice
Good manufacturing practice
View on Wikipedia
from Wikipedia
Food safety
Terms
Critical factors
Bacterial pathogens
Viral pathogens
Parasitic pathogens

Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages,[1] cosmetics,[2] pharmaceutical products,[3] dietary supplements,[4] and medical devices.[5] These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use.

The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user.[2] Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase.[2] GMP is typically ensured through the effective use of a quality management system (QMS).[1]: "The Basis for GMP",  [2]

Good manufacturing practice, along with good agricultural practice, good laboratory practice and good clinical practice, are overseen by regulatory agencies in the United Kingdom, United States, Canada, various European countries, China, India and other countries.

High-level details

[edit]

Good manufacturing practice guidelines provide guidance for manufacturing, testing, and quality assurance in order to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.

All guidelines follow a few basic principles:[2][6]

  • Manufacturing facilities must maintain a clean and hygienic manufacturing area.
  • Manufacturing facilities must maintain controlled environmental conditions in order to prevent cross-contamination from adulterants and allergens that may render the product unsafe for human consumption or use.
  • Manufacturing processes must be clearly defined and controlled. All critical processes are validated to ensure consistency and compliance with specifications.
  • Manufacturing processes must be controlled, and any changes to the process must be evaluated. Changes that affect the quality of the drug are validated as necessary.
  • Instructions and procedures must be written in clear and unambiguous language using good documentation practices.
  • Operators must be trained to carry out and document procedures.
  • Records must be made, manually or electronically, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were in fact taken and that the quantity and quality of the food or drug was as expected. Deviations must be investigated and documented.
  • Records of manufacture (including distribution) that enable the complete history of a batch to be traced must be retained in a comprehensible and accessible form.
  • Any distribution of products must minimize any risk to their quality.
  • A system must be in place for recalling any batch from sale or supply.
  • Complaints about marketed products must be examined, the causes of quality defects must be investigated, and appropriate measures must be taken with respect to the defective products and to prevent recurrence.

Good manufacturing practice is recommended with the goal of safeguarding the health of consumers and patients as well as producing quality products. In the United States, a food or drug may be deemed "adulterated" if it has passed all of the specifications tests but is found to be manufactured in a facility or condition which violates or does not comply with current good manufacturing guideline.

GMP standards are not prescriptive instructions on how to manufacture products. They are a series of performance based requirements that must be met during manufacturing.[7] When a company is setting up its quality program and manufacturing process, there may be many ways it can fulfill GMP requirements. It is the company's responsibility to determine the most effective and efficient quality process that both meets business and regulatory needs.[1]: "Decision Makers' Summary",  [2]

Regulatory agencies have recently begun to look at more fundamental quality metrics of manufacturers than just compliance with basic GMP regulations. US-FDA has found that manufacturers who have implemented quality metrics programs[8] gain a deeper insight into employee behaviors that impact product quality.

In its Guidance for Industry "Data Integrity and Compliance With Drug CGMP" US-FDA states “it is the role of management with executive responsibility to create a quality culture where employees understand that data integrity is an organizational core value and employees are encouraged to identify and promptly report data integrity issues.”[9] Australia's Therapeutic Goods Administration has said that recent data integrity failures have raised questions about the role of quality culture in driving behaviors.[10] In addition, non-governmental organizations such as the International Society for Pharmaceutical Engineering (ISPE) and the Parenteral Drug Association (PDA) have developed information and resources to help pharmaceutical companies better understand why quality culture is important and how to assess the current situation within a site or organization.[11]

Guideline versions

[edit]

GMP is enforced in the United States by the U.S. Food and Drug Administration (FDA), under Title 21 CFR. The regulations use the phrase "current good manufacturing practices" (CGMP) to describe these guidelines.[12][13][14][15] Courts may theoretically hold that a product is adulterated even if there is no specific regulatory requirement that was violated as long as the process was not performed according to industry standards.[16] However, since June 2007, a different set of CGMP requirements have applied to all manufacturers of dietary supplements, with additional supporting guidance issued in 2010.[4] Additionally, in the U.S., medical device manufacturers must follow what are called "quality system regulations" which are deliberately harmonized with ISO requirements, not necessarily CGMPs.[14]

The World Health Organization (WHO) version of GMP is used by pharmaceutical regulators and the pharmaceutical industry in over 100 countries worldwide, primarily in the developing world.[3] The European Union's GMP (EU GMP) enforces similar requirements to WHO GMP, as does the FDA's version in the US. Similar GMPs are used in other countries, with Australia, Canada, Japan, Saudi Arabia, Singapore, Philippines], Vietnam and others having highly developed/sophisticated GMP requirements.[17] In the United Kingdom, the Medicines Act (1968) covers most aspects of GMP in what is commonly referred to as "The Orange Guide," which is named so because of the color of its cover; it is officially known as Rules and Guidance for Pharmaceutical Manufacturers and Distributors.[18]

Since the 1999 publication of Good Manufacturing Practice for Active Pharmaceutical Ingredients, by the International Conference on Harmonization (ICH), GMPs now apply in those countries and trade groupings that are signatories to ICH (the EU, Japan and the U.S.), and applies in other countries (e.g., Australia, Canada, Singapore) which adopt ICH guidelines for the manufacture and testing of active raw materials.[17]

Enforcement

[edit]

Within the European Union GMP inspections are performed by National Regulatory Agencies. GMP inspections are performed in Canada by the Health Products and Food Branch Inspectorate;[19] in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA);[20] in the Republic of Korea (South Korea) by the Ministry of Food and Drug Safety (MFDS);[21] in Australia by the Therapeutic Goods Administration (TGA);[22] in Bangladesh by the Directorate General of Drug Administration (DGDA);[23] in South Africa by the Medicines Control Council (MCC);[24] in Brazil by the National Health Surveillance Agency (ANVISA);[25] in India by state Food and Drugs Administrations (FDA), reporting to the Central Drugs Standard Control Organization;[26] in Pakistan by the Drug Regulatory Authority of Pakistan;[27] in Nigeria by NAFDAC;[28] and by similar national organizations worldwide. Each of the inspectorates carries out routine GMP inspections to ensure that drug products are produced safely and correctly. Additionally, many countries perform pre-approval inspections (PAI) for GMP compliance prior to the approval of a new drug for marketing.

CGMP inspections

[edit]

Regulatory agencies (including the FDA in the U.S. and regulatory agencies in many European nations) are authorized to conduct unannounced inspections, though some are scheduled.[12][18][21][22][23][24][26][27][28] FDA routine domestic inspections are usually unannounced, but must be conducted according to 704(a) of the Food, Drug and Cosmetic Act (21 USCS § 374), which requires that they are performed at a "reasonable time". Courts have held that any time the firm is open for business is a reasonable time for an inspection.[29]

Other good practices

[edit]

Other good-practice systems, along the same lines as GMP, exist:

Collectively, these and other good-practice requirements are referred to as "GxP" requirements, all of which follow similar philosophies. Other examples include good guidance practice and good tissue practice.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Good manufacturing practice

View on Grokipedia
from Grokipedia
Good manufacturing practice (GMP), also known as current good manufacturing practice (cGMP) in some jurisdictions, is a system of regulations, guidelines, and procedures designed to ensure that products are consistently produced and controlled according to quality standards appropriate to their intended use, thereby minimizing risks such as , mix-ups, or deviations that cannot be fully addressed by final alone. GMP encompasses a comprehensive framework that covers all stages of production, from the sourcing of raw materials to the final and distribution of products. Key components include the design and maintenance of suitable facilities and equipment, rigorous personnel training and hygiene protocols, detailed written procedures for all processes, and systematic to demonstrate compliance and enable . These practices aim to build quality into the product from the outset, ensuring identity, strength, purity, and efficacy, as relying solely on end-product testing (e.g., sampling a small batch from a large production run) is insufficient to guarantee overall safety. The scope of GMP extends beyond pharmaceuticals to include , dietary supplements, , medical devices, and nutraceuticals, with tailored regulations for each sector to prevent adulteration and health hazards. For instance, in the , GMP focuses on preventing errors like incorrect labeling or improper levels to maintain therapeutic efficacy. In manufacturing, it addresses , plant design, , and production controls to mitigate risks from pathogens or foreign materials. Compliance with GMP not only safeguards but also enhances manufacturer credibility, reduces long-term costs through fewer recalls, and facilitates via harmonized standards. Regulatory oversight of GMP is provided by authoritative bodies such as the (WHO), which publishes global guidelines adopted or adapted by many countries, and the U.S. (FDA), which enforces cGMP through inspections and enforcement actions. Historically, FDA's cGMP for food was established in 1969 under 21 CFR Part 110 and modernized in 2015 under 21 CFR Part 117 as part of the Food Safety Modernization Act, incorporating risk-based preventive controls in response to evolving technologies and recognized hazards. Violations can result in product seizures, recalls, or legal penalties, underscoring GMP's role as a foundational element of regulatory compliance in controlled industries.

Fundamentals

Definition and Scope

Good manufacturing practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards appropriate to their intended use. This approach is designed to minimize risks inherent in production processes that cannot be fully eliminated through final , such as , mix-ups, errors, incorrect labeling, or deviations in levels that could lead to ineffective treatment or adverse effects. In the context of pharmaceuticals, GMP regulations enforced by authorities like the FDA provide for systems that assure the proper , monitoring, and control of processes and facilities to guarantee the identity, strength, quality, and purity of drug products. The scope of GMP encompasses the manufacturing, processing, packaging, and holding of products across several regulated industries, including pharmaceuticals, , , and . For instance, in the sector, GMP addresses hygienic practices, design, and to prevent adulteration, while in , it focuses on voluntary guidelines for safe production and labeling. Similarly, GMP, now integrated into requirements, ensures devices are safe and effective through controls on production and . Overall, GMP applies broadly to any operation where product quality directly impacts and safety. A key distinction exists between general GMP and current GMP (cGMP), particularly in jurisdictions like the , where the "current" designation emphasizes the need for ongoing updates to manufacturing systems to incorporate the latest scientific knowledge, technological advancements, and risk-based approaches. While GMP provides foundational principles for , cGMP requires dynamic, evidence-based improvements to prevent obsolescence and adapt to evolving standards.

Objectives and Benefits

The primary objectives of good manufacturing practice (GMP) are to ensure that pharmaceutical products are consistently produced to meet established standards, thereby guaranteeing their , , and purity for intended use. This involves building into every stage of the manufacturing process, from selection to final , to minimize risks such as , mix-ups, or deviations that could compromise product integrity. By protecting , GMP prevents the distribution of substandard or adulterated medicines that might lead to adverse outcomes, while also facilitating compliance with regulatory requirements for product authorization. Additionally, GMP supports by aligning with harmonized global standards, enabling manufacturers to export products without repeated requalification across borders. GMP plays a crucial role in by proactively addressing potential hazards, including adulteration, misbranding, or improper levels, which cannot be fully eliminated through end-product testing alone. This systematic approach requires documented procedures, trained personnel, and controlled facilities to identify and mitigate risks throughout production, ensuring that products remain fit for purpose and do not endanger patients. The benefits of implementing GMP are multifaceted, including reduced product variability through standardized processes that maintain consistent batch quality, thereby minimizing defects and enhancing reliability. This leads to greater consumer confidence in the safety and effectiveness of medicines, as well as cost savings for manufacturers from fewer recalls, rework, and regulatory penalties. For instance, adherence to GMP helps prevent adverse events by ensuring uniform product performance across batches, ultimately contributing to improved outcomes and efficient global supply chains.

Historical Development

Origins and Early Regulations

The origins of good manufacturing practice (GMP) can be traced to early 20th-century efforts in the United States to address risks from adulterated and unsafe food and drug products. The of 1906 marked a foundational step by prohibiting the interstate shipment of adulterated or misbranded foods and drugs, emphasizing the need for sanitary preparation and accurate labeling to prevent contamination during manufacturing. This legislation laid the groundwork for regulatory oversight of production processes, though it lacked detailed enforcement mechanisms for compliance. A pivotal incident that accelerated demands for stricter manufacturing standards was the 1937 Elixir Sulfanilamide disaster, in which a liquid formulation of the antibiotic , dissolved in toxic , caused 107 deaths due to inadequate safety testing and poor formulation practices. This tragedy exposed vulnerabilities in drug production and directly spurred the enactment of the Federal Food, Drug, and Cosmetic Act (FD&C Act) in 1938, which expanded FDA authority to regulate drugs more comprehensively by requiring proof of safety, prohibiting adulteration, and mandating sanitary manufacturing conditions to ensure product integrity. The 1938 Act thus served as a key precursor to GMP by implicitly requiring controls over facilities, equipment, and processes to avoid . The concept of GMP crystallized in the early 1960s amid growing concerns over drug quality and . The Kefauver-Harris Amendments of 1962, prompted by the crisis, amended the FD&C Act to require manufacturers to demonstrate both and through adequate scientific investigations before marketing new drugs, while also strengthening FDA oversight of to prevent variability in product quality. In response, the FDA issued its first official GMP regulations in 1963 (initially codified in 21 CFR Part 133), which outlined specific requirements for production, , and documentation to ensure consistent drug quality. The regulations were later revised and recodified in 21 CFR Parts 210 and 211 in 1978. Internationally, the (WHO) began formalizing GMP principles in the late 1960s to harmonize standards for pharmaceutical quality. In 1967, WHO consultants prepared the first draft text on GMP, which was discussed and adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1968; this document was integrated into the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International , established to verify compliance with manufacturing standards for exported drugs.

Key Milestones and Evolution

The 1970s marked a watershed in the formalization of good manufacturing practice (GMP) regulations, particularly , where the (FDA) issued its current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in 1978, establishing minimum requirements for methods, facilities, and controls to ensure drug product quality. These regulations, codified in 21 CFR Parts 210 and 211, built on earlier efforts by emphasizing preventive controls over end-product testing. In the same year, the FDA extended CGMP requirements to medical devices through a final rule under section 520(f) of the Federal Food, Drug, and Cosmetic Act, prescribing standards for production and process controls to mitigate risks in device manufacturing. The 1990s and 2000s saw significant strides toward international harmonization of GMP standards. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) was established in 1995 as an extension of the 1970 Pharmaceutical Inspection Convention, aiming to promote cooperation among regulatory authorities and facilitate mutual recognition of inspections to ensure consistent global compliance. In 1999, the International Council for Harmonisation (ICH) endorsed Q7, providing guidance on GMP for active pharmaceutical ingredients (APIs), which outlined principles for , personnel, premises, and documentation to harmonize API manufacturing practices across ICH regions. Over this period, GMP evolved from largely prescriptive rules to risk-based approaches that prioritize proactive quality management. A key example is the FDA's 2006 "Pharmaceutical CGMPs for the 21st Century" initiative, which introduced a quality systems model incorporating risk management to modernize regulations, foster innovation, and focus resources on higher-risk areas in pharmaceutical manufacturing. Similarly, the World Health Organization (WHO) updated its GMP guidelines in Technical Report Series (TRS) No. 999, Annex 2 (2016), for biological products, integrating quality risk management principles to systematically assess, control, and review risks throughout the product lifecycle. These developments reflected a broader shift toward integrated, science-based systems that enhance global supply chain reliability while adapting to complex manufacturing technologies.

Regulatory Frameworks

United States FDA CGMP

The Current Good Manufacturing Practice (CGMP) regulations in the United States are enforced by the Food and Drug Administration (FDA) primarily under 21 CFR Parts 210 and 211, which establish minimum standards for the methods, facilities, and controls used in the manufacturing, processing, packing, or holding of drugs to ensure their safety, identity, strength, quality, and purity. Part 210 provides the general framework, declaring that these regulations supplement other specific FDA rules (such as those for veterinary drugs or biologics) without superseding them, and non-compliance renders drugs adulterated under the Federal Food, Drug, and Cosmetic Act. Part 211 details the requirements for finished pharmaceuticals, organized into subparts covering organization, production, and quality assurance, emphasizing comprehensive systems for the design, monitoring, and control of manufacturing processes to prevent contamination, mixups, and deviations that could compromise product integrity. These regulations apply to all drug products for human and animal use, excluding certain investigational drugs in early phases, and extend to human cells, tissues, and cellular/tissue-based products regulated as drugs. Key provisions in Part 211 address critical aspects of operations to maintain product . For personnel qualifications, Subpart B requires a designated unit with the authority to approve or reject products and components, ensuring all staff are trained, qualified, and free from health conditions that could affect operations, with written procedures for and gowning to prevent . Buildings and sanitation under Subpart C mandate facilities designed to minimize risks, including adequate , , ventilation, , and cleaning programs to avoid cross-contamination, with separate areas for different operations and special isolation for penicillin production. Equipment maintenance in Subpart D, particularly 21 CFR § 211.67, mandates written procedures for cleaning and maintenance schedules, methods, responsibilities, and records, aligning with preventive maintenance to prevent malfunctions and contamination. All apparatus must be suitably located, designed, constructed, and calibrated, with routines for , maintenance, and automated process controls to ensure reliability and prevent malfunctions. Production records and controls in Subparts E, F, and G require written procedures for component testing, in-process monitoring, , , and , including validation of processes, of deviations, and safeguards against errors like label mixups. Laboratory testing under Subpart I demands specifications, standards, and testing methods for raw materials, in-process materials, and finished products to verify identity, strength, , and purity, along with stability studies to support expiration dating. The "current" designation in CGMP distinguishes these regulations from static standards by requiring manufacturers to employ up-to-date technologies, testing methods, and scientifically justified practices that evolve with advances in science and engineering, rather than relying solely on historical approaches. This flexibility promotes continual improvement, such as integrating real-time monitoring systems or risk-based process controls, while the FDA periodically updates guidance documents to reflect emerging evidence and innovations without altering the core CFR text unless through formal rulemaking. The FDA plays a pivotal role in CGMP enforcement through premarket approval processes, where it reviews manufacturing facility inspections and compliance data as part of new drug applications under 21 CFR Part 314, ensuring facilities meet standards before products are approved for marketing. Postmarket, the agency conducts surveillance via routine inspections by investigators and assessors, analyzes reports from industry and the public, and initiates actions such as warning letters, product seizures, or injunctions for violations, while also monitoring trends to inform future regulatory enhancements.

European Union EMA GMP

The (EMA) oversees the implementation of Good Manufacturing Practice (GMP) within the through a harmonized framework established by EU directives, primarily Directive 2001/83/EC for human medicines and Directive 2001/82/EC for veterinary medicines. This framework ensures the quality, safety, and efficacy of medicinal products manufactured or imported into the EU, applying uniformly across all 27 member states. Post-Brexit, the EMA's GMP regulations no longer extend to the , which operates under the Medicines and Healthcare products Regulatory Agency (MHRA) as a third country, necessitating separate compliance pathways for UK-based manufacturing sites supplying the EU market. The core GMP guidelines are detailed in EudraLex Volume 4, which provides comprehensive rules for interpreting GMP principles applicable to medicinal products for both human and veterinary use. This volume is structured into parts, with Part I outlining basic requirements through key chapters that form the foundation of EU GMP compliance. Chapter 1 addresses the pharmaceutical quality system, emphasizing a proactive approach to risk management and continual improvement. Chapter 2 covers personnel qualifications, training, and hygiene to ensure competent staff. Chapter 3 details requirements for premises and equipment, including design, maintenance, and validation to prevent contamination. Chapter 4 focuses on documentation practices, mandating clear, traceable records for all processes. Chapter 5 governs production operations, including validation of manufacturing processes and handling of starting materials. Chapter 6 specifies quality control measures, such as sampling, testing, and release procedures to verify product conformity. These chapters are regularly updated to incorporate scientific advancements and align with international standards, such as those from the International Council for Harmonisation (ICH). In response to the , the EMA's GMP/GDP Inspectors Working Group implemented temporary extensions for the validity of GMP certificates that expired during periods of restricted inspections, prolonged until the end of 2024 to accommodate global disruptions. From 2025, these extensions cease, reinstating full GMP inspection requirements to maintain rigorous oversight of sites. This shift ensures that all certificates reflect current compliance status, with inspections resuming at pre-pandemic levels to uphold product quality. To facilitate efficient regulation, the maintains mutual recognition agreements (MRAs) for GMP inspections with select non- countries, including the . Under the EU-US MRA, effective since 2017 for human medicines and extended to veterinary products in 2023, the EMA recognizes FDA-inspected sites as equivalent, reducing redundant audits and enhancing global reliability. This agreement covers inspections of manufacturing facilities, allowing reliance on each other's findings for certificate issuance. As of October 1, 2025, this reliance extends to FDA inspections conducted at sites outside the US and .

World Health Organization WHO GMP

The (WHO) develops Good Manufacturing Practice (GMP) guidelines that function as an international reference, especially supporting regulatory authorities and manufacturers in developing countries to ensure the quality of for programs. These standards are published in the WHO Technical Report Series (TRS), with foundational documents such as Annex 2 of TRS 986 (2014), which details the main principles for pharmaceutical products, including provisions for sterile manufacturing that prioritize practical implementation in low-resource settings. WHO also publishes the Quality assurance of pharmaceuticals: a compendium of guidelines and related materials, with volumes dedicated to good manufacturing practices, inspection, and quality assurance. Central to WHO GMP are principles of , which require a comprehensive Pharmaceutical Quality System (PQS) to systematically manage all aspects of production, ensuring products are fit for their intended use and free from risks to patients. This encompasses good practices in production, mandating clearly defined and validated processes to achieve consistent , prevent cross-contamination, and maintain environmental controls. Additionally, good practices in emphasize sourcing from approved suppliers with agreed specifications, coupled with thorough testing and documentation of starting materials to uphold integrity. These elements collectively aim to produce safe, effective medicines while optimizing resource use. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) provides an additional international GMP resource through its Guide to Good Manufacturing Practice for Medicinal Products, which is aligned with EU GMP and supports harmonized inspections among participating authorities, many of which are outside the EU. WHO GMP integrates closely with the Prequalification Programme for medicines and vaccines, launched in 2001 to address urgent needs during the pandemic by evaluating products for quality, safety, and efficacy. Under this program, manufacturing sites undergo GMP inspections to verify compliance, enabling prequalification of for procurement by agencies, international aid organizations, and governments in low- and middle-income countries, thereby facilitating equitable access to treatments for priority diseases like and . Unlike more prescriptive regional frameworks, WHO GMP provides adaptable guidelines tailored to resource-limited environments, permitting flexible application of requirements—such as in facility design or testing protocols—provided equivalence to core quality standards is demonstrated, with an overarching emphasis on critical for in developing nations.

Core Requirements

Quality Management Systems

A Quality Management System (QMS) in Good Manufacturing Practice (GMP) provides a comprehensive framework for ensuring consistent product quality and compliance throughout the product lifecycle, from development to distribution, across various industries such as pharmaceuticals, food, and medical devices. For pharmaceuticals, it integrates organizational structure, processes, resources, and activities to achieve product realization and maintain a state of control, as outlined in the ICH Q10 guideline. Similar frameworks apply in other sectors, such as for management. This system emphasizes proactive management to prevent quality issues rather than merely detecting them post-occurrence. Central to the QMS is the establishment of a by , which defines the organization's commitment to , , and continual improvement. This policy guides the setting of specific objectives that are measurable and aligned with goals, ensuring all activities support product , , and . Adequate resources, including human, financial, and infrastructural support, are allocated to meet these objectives, fostering an environment where is embedded in every . The QMS operates on the Plan-Do-Check-Act (PDCA) cycle for continual improvement, where processes are planned, implemented, monitored through performance indicators, and acted upon via corrective and preventive actions (CAPA). This cyclical approach enables ongoing evaluation and enhancement, reducing the likelihood of deviations and ensuring sustained compliance. Knowledge management is a key element, involving the systematic generation, capture, and utilization of product and process across the lifecycle to inform decisions and mitigate risks. Risk management, as detailed in ICH Q9, is integrated into the QMS to identify, assess, and control potential risks using science-based principles and tools such as (FMEA). This proactive strategy prioritizes patient protection by applying formality and documentation proportional to the level, enhancing decision-making in GMP operations. processes form another critical component, requiring formal evaluation, approval, and implementation of any modifications to prevent unintended impacts on product . Foundational tools within the QMS include the quality manual, which documents the , system scope, and key processes; Standard Operating Procedures (SOPs), which standardize operations to ensure consistency; and internal audits, which independently assess compliance and effectiveness, driving improvements. These elements collectively prevent deviations by embedding oversight and feedback mechanisms, while safeguarding quality from development through and distribution.

Personnel, Facilities, and Equipment

Good manufacturing practice (GMP) requires that personnel involved in manufacturing possess appropriate qualifications, training, and experience to perform their duties effectively and minimize risks of contamination. In the pharmaceutical sector, under U.S. FDA regulations, each individual engaged in manufacturing, processing, packing, or holding drug products must have the education, training, or experience—or a combination thereof—to enable them to perform assigned functions, with ongoing training provided to maintain proficiency. Similarly, the European Medicines Agency (EMA) emphasizes specialized training in microbiology, hygiene, and aseptic techniques for personnel in sterile product areas, including annual reassessments of gowning proficiency to ensure compliance. The World Health Organization (WHO) GMP guidelines reinforce this by mandating documented training programs and health monitoring to prevent personnel from introducing contaminants, such as through regular medical surveillance for those handling hazardous materials. Hygiene practices are critical, with personnel required to wear clean clothing appropriate to their tasks, report any conditions that could adversely affect products, and follow strict protocols to avoid . In sterile environments, gowning procedures involve sterile suits, gloves, masks, and eye coverings for Grade A/B areas, verified through microbial monitoring and media fills. Only the minimum number of personnel should enter cleanrooms to reduce risks, and access must be controlled to qualified individuals. Facilities under GMP must be designed, constructed, and maintained to facilitate cleaning, prevent mix-ups, and control contamination, with adequate space for operations and segregation of activities. FDA requirements specify buildings of suitable size and location, featuring proper lighting, ventilation, air filtration, and plumbing to avoid adulteration, including separate areas for receipt, storage, and manufacturing. In sterile manufacturing, EMA guidelines classify cleanrooms into Grades A-D, requiring unidirectional airflow (0.36–0.54 m/s) in Grade A zones, positive pressure differentials, smooth impervious surfaces without recesses, and no sinks or drains in higher grades to maintain sterility. WHO standards similarly call for dedicated, self-contained facilities with air-handling systems, changing rooms equipped with showers, and pressure cascades monitored via alarms to ensure containment. Sanitation programs must include written procedures for cleaning facilities, to eliminate , and routine maintenance to keep structures in good repair. Environmental monitoring in controlled areas involves continuous assessment of particles, , , and , with requalification every 6–12 months depending on the grade. Segregation is achieved through airlocks, restricted access barriers (RABS), or isolators, preventing cross-contamination between clean and unclean operations. Equipment must be of appropriate design, size, and construction to suit its intended use, facilitate cleaning and maintenance, and avoid reactions with products or contamination. FDA CGMP mandates non-reactive, non-additive materials for equipment surfaces, with written procedures for production, cleaning, and preventive maintenance to ensure reliability and prevent malfunctions. Preventive maintenance programs for pharmaceutical processing systems are systematic, scheduled activities to clean, inspect, calibrate, lubricate, and repair equipment, preventing failures, contamination, and ensuring drug product quality, safety, and efficacy. These programs include written procedures covering maintenance schedules, methods, responsibilities, and record-keeping to comply with regulations and minimize downtime, as mandated by 21 CFR § 211.67. Calibration of automatic, mechanical, and electronic devices is required according to a scheduled program, including inspections and adjustments, while computer systems must have secure controls and data backups. Cleaning validation is essential, demonstrating that residues are removed to safe levels through detailed procedures, sampling (e.g., swabs or rinses), and analytical testing with predefined limits. In sterile settings, EMA requires qualification, including sterilization validation via temperature mapping for processes like or dry heat, and regular integrity testing of filters. schedules must address both planned and unplanned activities, assessing impacts on sterility, to uphold performance throughout its lifecycle.

Documentation, Production, and Quality Controls

Documentation in good manufacturing practice (GMP) encompasses the creation, maintenance, and retention of records that ensure , , and compliance with regulatory standards. Standard operating procedures (SOPs) outline detailed instructions for all manufacturing and activities, including system suitability testing and data reprocessing, to maintain under principles like (attributable, legible, contemporaneous, original, and accurate). Batch production records document the execution of each manufacturing step, including actual yields, deviations, and operator signatures, serving as master production and control records (MPCRs) that must be validated for accuracy. Validation protocols specify testing conditions, acceptance criteria, and expected outcomes for processes, facilities, and equipment, with comprehensive documentation required during process qualification to confirm reproducibility. For electronic systems, records and signatures must comply with 21 CFR Part 11, ensuring trustworthiness through controls like audit trails, access restrictions, and validation, though enforcement discretion applies to legacy systems predating 1997 if they meet predicate rules. Production controls in GMP focus on establishing and monitoring manufacturing processes to prevent errors and ensure consistent product quality. Process validation involves three stages—process design, process qualification, and continued process verification—to collect and evaluate data demonstrating that the process yields products meeting specifications, as required under 21 CFR 211.100(a) and 211.110(a). During production, in-process checks monitor critical parameters such as material verification, equipment performance, and environmental conditions, with written procedures defining acceptance criteria approved by the quality unit to detect variability early. Yield reconciliation compares actual yields against expected ranges derived from historical data, triggering investigations for deviations in critical steps to assess potential quality impacts and prevent discrepancies. These controls are documented in batch records and reviewed periodically to maintain process integrity. While these examples draw from pharmaceutical regulations, analogous controls apply in other GMP sectors like food manufacturing. Quality controls verify that materials, in-process samples, and finished products meet predefined specifications through systematic testing and . Sampling follows statistically sound plans to ensure representativeness, with in-process sampling designed to avoid and support monitoring without requiring out-of-specification (OOS) investigations unless release testing is affected. Testing employs validated analytical methods, such as (HPLC) for purity and impurity profiling, using characterized reference standards to confirm identity, assay, and degradation products. Stability studies assess product shelf-life under accelerated and long-term conditions, requiring stability-indicating methods to detect changes in attributes like potency and impurities, as per 21 CFR 211.166(a)(3). Release criteria include numerical limits for assays (e.g., 95-105% of label claim), impurity thresholds, and dissolution rates, justified by development data and approved by the unit before batch distribution. Integrated into these systems are procedures for complaint handling, deviation investigations, and recall procedures to address potential quality issues post-production. Complaints must be recorded and investigated per written SOPs to identify trends or defects, with the qualified person involved in evaluations. Deviation investigations classify events by risk (minor, major, critical) using tools like (FMEA), employing root cause analysis methods such as the "5 Whys" to implement corrective and preventive actions (CAPA). Recall procedures outline rapid evaluation, initiation, and notification for distributed products posing risks, ensuring documentation of all actions to trace and quarantine affected batches. These mechanisms, supported by quality risk management, reinforce overall GMP compliance by linking production and quality data to proactive issue resolution.

Compliance and Enforcement

Inspections and Audits

Inspections and audits are essential mechanisms for verifying adherence to good manufacturing practice (GMP) standards in regulated industries, ensuring product , , and . Regulatory authorities conduct these reviews to assess compliance with established guidelines, while manufacturers perform internal audits to proactively maintain standards. These processes help identify deviations and support continuous improvement in operations. In the United States, the (FDA) conducts several types of GMP inspections, including surveillance inspections, which are routine and risk-based evaluations to monitor ongoing compliance at facilities. For-cause inspections are initiated in response to specific concerns, such as reports or complaints, to investigate potential violations. These inspections typically involve on-site assessments by FDA investigators who examine processes and documentation over several days. The (EMA), in coordination with national competent authorities, performs GMP audits that include both on-site and remote formats. On-site audits are the standard approach, involving physical visits to manufacturing sites to evaluate operations, particularly for medicines under centralized authorization procedures. Remote audits, increasingly utilized since the , allow for document reviews and virtual assessments to address compliance backlogs, though they are often supplemented by on-site follow-ups when feasible. The scope of these inspections and audits encompasses a thorough review of systems (QMS), facilities, equipment, production records, and procedures. Auditors may conduct mock recalls to test and response capabilities, ensuring systems can effectively manage potential contamination or errors. In FDA inspections, any observed objectionable conditions are documented on , which lists factual observations without including opinions or unverified issues, prioritized by risk significance. Internal audits, also known as self-inspections, are a core GMP requirement where manufacturers systematically evaluate their own operations to detect and correct gaps before external reviews occur. These programs involve independent, documented assessments of all GMP elements, such as personnel , practices, and , often scheduled regularly to align with regulatory expectations. By identifying issues early, self-inspections help mitigate risks and demonstrate a commitment to . Global harmonization of inspections is advanced through the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which promotes mutual recognition of GMP inspections among member authorities to reduce duplication and enhance efficiency. PIC/S develops common standards and training for inspectors, enabling reliance on one another's assessments for sites exporting to multiple regions. This framework supports while maintaining consistent quality oversight.

Violations, Penalties, and Corrective Actions

Non-compliance with Good Manufacturing Practice (GMP) regulations can result in a range of enforcement actions by regulatory authorities, aimed at protecting by addressing deficiencies in product quality and safety. In the United States, the (FDA) commonly issues warning letters to manufacturers found in violation of Current Good Manufacturing Practice (CGMP) requirements, detailing specific issues such as inadequate or facility sanitation and requiring corrective measures within specified timelines. If violations persist or pose significant risks, the FDA may escalate to import alerts, which prevent violative products from entering the U.S. market, or initiate product seizures to remove unsafe goods from commerce. Additionally, under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA may pursue civil court actions such as injunctions for ongoing violations, particularly in cases involving adulterated or misbranded products. For willful or intentional GMP violations, criminal penalties apply under the FD&C Act, including fines and . A first-time can result in up to one year of and a fine of up to $1,000 per individual, while subsequent offenses or felonies—such as those involving intent to defraud—may lead to up to three years and fines up to $10,000, with organizational fines potentially escalating to $500,000 under alternative fine provisions. In the , enforcement of GMP under Directive 2003/94/EC is handled by national competent authorities, with penalties varying by but typically including administrative fines, suspension or revocation of manufacturing authorizations, and product recalls. Criminal sanctions for serious or repeated violations, such as those endangering , can involve and substantial fines, though exact amounts differ; for instance, in , fines can exceed €500,000, while in , they may reach €300,000 with up to five years for aggravated cases. To address identified violations, manufacturers must implement Corrective and Preventive Actions (CAPA) as a core GMP requirement, focusing on root cause analysis to eliminate underlying issues rather than superficial fixes. The CAPA process involves investigating deviations through tools like the "5 Whys" or fishbone diagrams, developing actionable plans with clear implementation timelines—often 30-90 days depending on risk—and conducting effectiveness checks, such as audits or monitoring, to verify sustained compliance. Failure to adequately execute CAPA can lead to further enforcement, emphasizing its role in preventing recurrence and ensuring ongoing quality management. Recent FDA enforcement actions illustrate these measures, particularly in sterile facilities where risks are high. Between 2023 and 2025, the FDA issued multiple warning letters to pharmacies for CGMP violations, including inadequate environmental controls and sterility assurance; for example, in April 2025, Empower Clinic Services, LLC (dba Empower Pharma) received a warning letter for failures in microbial prevention during sterile production, following a prior 2023 inspection. Similarly, in July 2025, Exela Pharma Sciences, LLC was cited for significant CGMP deficiencies in sterile injectable , leading to alerts and required CAPA submissions. These cases underscore the FDA's intensified scrutiny on , resulting in over 20 such actions in 2024-2025 alone, often involving product recalls and facility closures until compliance is demonstrated.

Industry Applications

Pharmaceuticals and Biologics

Good manufacturing practice (GMP) for pharmaceuticals and biologics is tailored to ensure the quality, safety, and of substances and products, with stringent controls to address risks unique to , biological processes, and sterility requirements. In the pharmaceutical sector, GMP emphasizes the production of active pharmaceutical ingredients (APIs) and finished , while biologics manufacturing incorporates additional safeguards for living organisms and complex biomolecules. These adaptations prioritize prevention, , and to mitigate risks such as impurities, degradation, or adventitious agents that could compromise therapeutic outcomes. For APIs, the International Council for Harmonisation (ICH) Q7 guideline establishes specific requirements to maintain integrity throughout the manufacturing lifecycle. is achieved through comprehensive records that include unique batch numbers, production dates, equipment identifiers, and batch details, enabling full tracking from receipt to distribution for potential recalls. Cross-contamination prevention mandates dedicated facilities for highly sensitizing materials like beta-lactams, validated cleaning procedures for shared equipment with defined residue acceptance criteria, and controls on material carryover to avoid altering impurity profiles. Reprocessing of intermediates or APIs is permitted only under written procedures evaluated by the quality unit, ensuring no adverse impact on quality, with reworked batches requiring additional testing and to match original specifications. Biologics manufacturing under GMP incorporates specialized controls for cellular and molecular complexities, as outlined in ICH Q5A(R2). Cell bank management involves establishing and testing Master Cell Banks (MCB) and Working Cell Banks (WCB) for adventitious viruses using assays, tests, retrovirus detection, and next-generation sequencing, with the Limit of In Vitro Cell Age (LIVCA) similarly evaluated to ensure consistency up to commercial scale. Viral clearance validation requires process characterization with nonspecific model viruses to demonstrate robustness and evaluation with relevant or specific viruses to quantify removal/inactivation, targeting at least a 4 log10 reduction per step across multiple orthogonal methods like low pH treatment or nanofiltration, validated in at least two independent runs. considerations integrate risk assessments based on cell line origin (e.g., well-characterized cells require less extensive testing), with controls to address endogenous retroviruses and overall process design to minimize human infectivity risks. Sterile pharmaceuticals demand rigorous aseptic controls per the GMP Annex 1, focusing on preventing microbial contamination in products unable to support preservative efficacy. Aseptic processing occurs in Grade A environments with a Grade B background, utilizing barrier technologies like isolators or Restricted Access Barrier Systems (RABS) to limit interventions, with validated time limits for holding and maximum campaign durations to reduce exposure risks. Media fills, or aseptic process simulations, validate these operations by mimicking production runs with nutrient media, requiring at least three consecutive successful trials annually or post-changes, targeting zero growth in 5,000–10,000 units under worst-case conditions including operator simulations. is continuous in Grade A zones for viable (e.g., 0 CFU limits) and non-viable particles (e.g., ≤3,520 particles ≥0.5 μm/m³), with , alert/action limits, and microbial identification to species level in Grades A/B, supported by qualified systems and periodic requalification. During the , GMP compliance proved pivotal in accelerating production while upholding safety, as evidenced by case studies of mRNA and inactivated . For instance, Pfizer-BioNTech's scaled rapidly under GMP through early infrastructure investments and regulatory collaborations, achieving billions of doses without major quality lapses despite supply chain strains. Similarly, Sinovac's , produced in GMP facilities, underwent Phase 3 trials in demonstrating and safety in over a million participants, highlighting how standardized viral clearance and sterility controls enabled global distribution. Challenges included shortages and facility expansions in developing regions, underscoring the need for flexible GMP adaptations to balance speed and rigor in emergencies.

Food, Cosmetics, and Medical Devices

Good manufacturing practices (GMP) for , , and medical devices emphasize prevention, product , and compliance with sector-specific regulations, often tailored to address hazards rather than therapeutic . In these areas, GMP standards integrate to identify and mitigate risks such as microbial growth, allergens, or material degradation, while allowing flexibility for non-sterile products compared to pharmaceutical requirements. For food production, the U.S. (FDA) enforces current good manufacturing practices (CGMPs) under 21 CFR Part 117, which were modernized through the Food Safety Modernization Act (FSMA) of 2011 to prioritize preventive controls over reactive measures. FSMA requires registered food facilities to develop a plan that includes and risk-based preventive controls (HARPC), a science-based approach akin to Hazard Analysis and Critical Control Points (HACCP) principles used in , , and processing. Under HARPC, facilities must evaluate known or reasonably foreseeable hazards—biological, chemical, physical, or radiological—and implement controls such as protocols, supplier verification, and process monitoring to prevent contamination. HACCP integration extends to broader food categories via FSMA, requiring critical limits, monitoring procedures, corrective actions, and verification activities like environmental sampling to ensure ongoing effectiveness. Allergen controls form a critical component of food GMP, with FSMA explicitly mandating written procedures to prevent cross-contact during , , and holding, alongside accurate labeling of major food allergens (e.g., , eggs, ). These controls include dedicated , air to avoid airborne s, and employee training to minimize risks from the nine major food allergens, as defined in the Federal Food, Drug, and Cosmetic Act (as amended by the Food Allergy Safety, Treatment, Education, and Research Act of 2021), including , eggs, , crustacean shellfish, nuts, , , soybeans, and . In January 2025, the FDA updated its guidance on food labeling to refine definitions for certain allergens like , eggs, and nuts, supporting enhanced verification of preventive controls. Shelf-life testing integrates into verification of preventive controls, where facilities assess stability under storage conditions to control hazards like growth or chemical degradation, often through accelerated testing or real-time monitoring as part of the food safety plan. In cosmetics manufacturing, GMP is voluntary but guided by FDA's 2013 "Guidance for Industry: Cosmetic Good Manufacturing Practices," which recommends practices to prevent adulteration under the Federal Food, Drug, and Cosmetic Act. These guidelines align with international standards like ISO 22716:2007, focusing on through facility design, personnel , testing, and production controls to ensure product integrity. Microbial limits are a key emphasis, requiring routine testing of water, ingredients, in-process materials, and finished products for objectionable microorganisms, with preservation systems validated to inhibit growth during and consumer use. For over-the-counter (OTC) cosmetics, such as antiperspirants or sunscreens treated as drugs, GMP incorporates additional requirements like tamper-resistant for certain products (e.g., liquid items under 21 CFR 700.25) and documentation to support potential recalls, including lot tracking and distribution records. Medical device GMP is codified in the Quality System Regulation (QSR) under 21 CFR Part 820, which establishes requirements for , production, , labeling, installation, and servicing to ensure devices are and effective. (21 CFR 820.30) mandate procedures for planning, input verification, output review, transfer to manufacturing, validation, and changes, applying to all finished devices including those under investigational exemptions. Sterilization validation falls under (21 CFR 820.75), requiring manufacturers to confirm that sterilization methods (e.g., or ) consistently achieve sterility assurance levels, with protocols including installation qualification, operational qualification, and performance qualification. In 2024, FDA amended the QSR to incorporate :2016 by reference, harmonizing U.S. requirements with this international standard for systems while retaining unique elements like complaint handling and medical device reporting. Compared to pharmaceutical GMP, standards for , , and non-sterile s are generally less stringent, lacking mandatory or extensive batch testing for non-critical items and instead emphasizing to address contamination risks. For instance, GMP prioritizes sanitary operations and prevention without pharmaceutical-level documentation, while rely on voluntary microbial controls rather than enforced stability studies, and GMP focuses on verification over potency assays.

Recent Developments

2024-2025 Updates

In January 2025, the U.S. (FDA) issued a draft guidance document titled "Considerations for Complying with 21 CFR 211.110," which provides recommendations for ensuring batch uniformity and drug product integrity under current good manufacturing practice (CGMP) regulations for drugs. This guidance emphasizes enhancements to , including the identification of critical quality attributes, scientifically justified sampling and testing strategies, and the integration of process models with in-process controls to support advanced manufacturing techniques such as continuous manufacturing and real-time release testing. Manufacturers are required to submit comments on the draft by April 7, 2025, to inform the finalization of these improvements, aiming to strengthen oversight by the quality unit for adjustments within preapproved limits. The European Medicines Agency (EMA) reinstated full good manufacturing practice (GMP) inspections in 2025, ending extensions granted during 2024 that had been implemented due to flexibilities related to the COVID-19 pandemic and post-Brexit adjustments. These extensions, which automatically prolonged the validity of GMP and good distribution practice (GDP) certificates until the end of 2024 or the next on-site inspection, ceased applying from January 2025, requiring national competent authorities to conduct inspections on a case-by-case basis without blanket deferrals. This shift ensures a return to standard compliance verification, with the EMA's GMP/GDP Inspectors Working Group prioritizing the completion of backlog inspections and enhancing supply chain integrity through increased on-site assessments. In July 2025, the published draft revisions to Volume 4 GMP guidelines, including updates to Chapter 4 on , Annex 11 on computerized systems, and a new Annex 22 on the use of (AI) and in the manufacture of active substances and medicinal products. These drafts emphasize in electronic systems and records, robust cybersecurity measures for digital infrastructures, and risk-based validation principles for AI applications in process monitoring and quality controls. The period ended in October 2025, with the revisions aimed at supporting while ensuring compliance and in GMP environments. The (WHO) published Technical Report Series (TRS) No. 1060 in April 2025, which includes new GMP guidelines for excipients used in pharmaceutical products (Annex 3) and good practice considerations for the prevention and control of nitrosamines (Annex 2), along with updates on bioanalytical method validation and practices for blood establishments. These 2024-2025 regulatory developments have heightened emphasis on and cybersecurity within GMP frameworks, as vulnerabilities in global manufacturing networks and digital infrastructures pose risks to product quality and . For instance, EMA's work plan for 2025-2027 prioritizes integrity through enhanced and inspector training, while updates to computerized systems guidelines (such as EU GMP Annex 11 revisions) mandate robust cybersecurity measures to protect against threats in digital documentation and AI-integrated controls. This focus aims to build resilient manufacturing ecosystems capable of withstanding disruptions. The integration of Industry 4.0 technologies into good manufacturing practice (GMP) is transforming pharmaceutical production by enabling real-time monitoring and predictive analytics. The U.S. (FDA) highlights (AI) applications for process monitoring using sensor data, fault detection, and predictive , which align with current GMP (CGMP) requirements to enhance product and . Similarly, (IoT) devices facilitate continuous data collection for equipment maintenance and , supporting a shift toward data-driven in environments. Continuous manufacturing represents another key trend, moving away from batch processes to streamline operations and reduce variability; the International Council for Harmonisation (ICH) Q13 guideline provides a framework for its development, implementation, and lifecycle management, ensuring regulatory alignment across jurisdictions. Harmonization efforts are advancing through expanded ICH guidelines and international collaborations to standardize GMP practices globally. ICH Q12 on technical and regulatory considerations for pharmaceutical management introduces risk-based change categorization, established conditions for critical quality elements, and post-approval protocols, reducing regulatory burdens and facilitating while maintaining GMP compliance. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) supports digitalization via guidance on remote assessments, including fully interactive video-based audits and hybrid models, which promote and reliance among member authorities for GMP inspections. These initiatives build on prior ICH quality guidelines to ensure predictable post-approval modifications, benefiting patients and industry by minimizing disruptions from varying regional requirements. Emerging challenges in GMP include adapting to climate impacts on supply chains and the unique demands of . exacerbates supply chain vulnerabilities through events that disrupt transportation and sourcing, complicating adherence to GMP standards for temperature-controlled and product stability. For , such as cell and gene therapies, GMP requirements necessitate stringent facility controls and validation to handle small-batch, patient-specific production, yet challenges arise in scaling operations while ensuring consistent quality and . Projections indicate that by 2030, risk-based remote inspections will become a standard component of GMP oversight, integrating digital tools for efficiency amid global resource constraints. PIC/S guidance positions hybrid inspections as an enduring approach, combining remote document reviews and virtual interactions with on-site elements to focus on high-risk areas, a trend expected to evolve with advancing technology. This shift supports broader harmonization goals, enabling regulators like the FDA and to prioritize critical compliance issues without compromising thoroughness.

References

  1. https://www.who.int/news-room/questions-and-answers/item/medicines-good-manufacturing-processes
  2. https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp
  3. https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements/current-good-manufacturing-practices-cgmps-food-and-dietary-supplements
  4. https://www.fda.gov/cosmetics/cosmetics-guidance-documents/good-manufacturing-practice-gmp-guidelinesinspection-checklist-cosmetics
  5. https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp
  6. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
  7. https://www.fda.gov/media/187861/download
  8. https://www.fda.gov/about-fda/changes-science-law-and-regulatory-authorities/part-i-1906-food-and-drugs-act-and-its-enforcement
  9. https://www.nlm.nih.gov/exhibition/phs_history/foodanddrugs.html
  10. https://www.fda.gov/about-fda/fda-history/milestones-us-food-and-drug-law
  11. https://www.ncbi.nlm.nih.gov/books/NBK585046/
  12. https://www.fda.gov/about-fda/histories-product-regulation/promoting-safe-effective-drugs-100-years
  13. https://biomanufacturing.org/uploads/files/305429596362804820-brief-history-of-gmps.pdf
  14. https://www.ispe.gr.jp/ISPE/02_katsudou/pdf/201804_en.pdf
  15. https://www.fda.gov/media/71023/download
  16. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
  17. https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments
  18. https://picscheme.org/en/about-introduction
  19. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry
  20. https://www.fda.gov/media/77391/download
  21. https://www.who.int/docs/default-source/biologicals/gmp/annex-2-who-good-manufacturing-practices-for-biological-products.pdf
  22. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210
  23. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-D/section-211.67
  24. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
  25. https://www.ema.europa.eu/en/about-us/history-ema/brexit-united-kingdoms-withdrawal-european-union/brexit-related-guidance-companies
  26. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  27. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice
  28. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/mutual-recognition-agreements-mra
  29. https://www.ema.europa.eu/en/documents/other/qa-impact-eu-usa-mutual-recognition-agreement-marketing-authorisation-applications-relevant-variations-revised-1st-october-2025_en.pdf
  30. https://www.who.int/publications/i/item/9789240086081
  31. https://www.who.int/publications/i/item/9789240099425
  32. https://www.who.int/publications/m/item/trs986-annex2
  33. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/trs986annex2.pdf?sfvrsn=320c9e62_1
  34. https://picscheme.org/docview/6606
  35. https://extranet.who.int/prequal/medicines/overview-history-mission
  36. https://www.who.int/news-room/fact-sheets/detail/prequalification-of-medicines-by-who
  37. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
  38. https://database.ich.org/sites/default/files/Q9_Guideline.pdf
  39. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-B/section-211.25
  40. https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf
  41. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1044-annex-2-gmp-for-sterile-pharmaceutical-products.pdf
  42. https://www.fda.gov/files/drugs/published/Data-Integrity-and-Compliance-With-Current-Good-Manufacturing-Practice-Guidance-for-Industry.pdf
  43. https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf
  44. https://www.fda.gov/media/75414/download
  45. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-7-good-manufacturing-practice-active-pharmaceutical-ingredients-step-5_en.pdf
  46. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products-chemical-substances-step-5_en.pdf
  47. https://www.fda.gov/drugs/guidances-drugs/questions-and-answers-current-good-manufacturing-practice-requirements-laboratory-controls
  48. https://dcvmn.org/wp-content/uploads/2016/03/who_guidance_deviation_and_risk_mgt_2013.pdf
  49. https://www.fda.gov/media/89231/download
  50. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/types-fda-inspections
  51. https://www.ema.europa.eu/en/news/international-regulators-reflections-remote-approaches-gcp-and-gmp-regulatory-oversight-during-covid-19-pandemic
  52. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspectional-observations-and-citations
  53. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  54. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients
  55. https://picscheme.org/docview/2682
  56. https://picscheme.org/templates/newsletters/newsletter.php?newsletter_id=8
  57. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
  58. https://www.fda.gov/industry/actions-enforcement/import-alerts
  59. https://www.law.cornell.edu/uscode/text/21/333
  60. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/corrective-and-preventive-actions-capa
  61. https://health.ec.europa.eu/document/download/080c6aed-4f09-4a8a-b052-3414275945db_en
  62. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharma-700962-04022025
  63. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/exela-pharma-sciences-llc-709859-07022025
  64. https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  65. https://www.fda.gov/files/drugs/published/Q7-Good-Manufacturing-Practice-Guidance-for-Active-Pharmaceutical-Ingredients-Guidance-for-Industry.pdf
  66. https://www.fda.gov/media/163115/download
  67. https://www.sciencedirect.com/science/article/pii/S0264410X23014779
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC9891391/
  69. https://www.fda.gov/food/current-good-manufacturing-practices-cgmps-food-and-dietary-supplements/good-manufacturing-practices-21st-century-food-processing-2004-study-appendix-e-comparison-food-gmps
  70. https://www.fda.gov/food/food-safety-modernization-act-fsma/fsma-final-rule-preventive-controls-human-food
  71. https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements/hazard-analysis-critical-control-point-haccp
  72. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/food-allergies
  73. https://www.fda.gov/food/food-allergensgluten-free-guidance-documents-regulatory-information/frequently-asked-questions-food-allergen-labeling-guidance-industry
  74. https://www.fda.gov/media/86366/download
  75. https://www.fda.gov/media/177022/download
  76. https://www.fda.gov/media/184825/download
  77. https://www.arnoldporter.com/en/perspectives/advisories/2025/01/fda-guidance-good-manufacturing-practices-for-drugs
  78. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/compliance-post-authorisation/good-distribution-practice
  79. https://www.ema.europa.eu/en/documents/work-programme/three-year-work-plan-good-manufacturing-practice-good-distribution-practice-inspectors-working-group-2025-2027_en.pdf
  80. https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en
  81. https://www.who.int/publications/m/item/trs-1060---annex-3--who-good-manufacturing-practices-for-excipients-used-in-pharmaceutical-products
  82. https://www.gmp-compliance.org/gmp-news/who-trs-1060-regulatory-guidelines-published
  83. https://www.fda.gov/media/165743/download
  84. https://www.ema.europa.eu/en/ich-guideline-q13-continuous-manufacturing-drug-substances-and-drug-products-scientific-guideline
  85. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf
  86. https://picscheme.org/docview/9256
  87. https://vpharmahorizon.com/climate-change-and-its-impact-on-the-drug-supply-chain/
  88. https://www.sciencedirect.com/science/article/pii/S0958166920300628
  89. https://www.innovx.org/post/adapting-to-the-future-of-gmp-compliance-key-takeaways-from-the-pic-s-guidance-on-remote-assessment
Add your contribution
Related Hubs
User Avatar
No comments yet.